Details

Autor(en) / Beteiligte

• Clé, Diego V.
• Hirayama, Alexandre V.
• Alencar, Alvaro J.
• Costa, Luciano J.
• Feliciano, João V.P.
• Mattos, Ederson R.
• Cordeiro, Ana C.
• Salvino, Marco Aurélio
• Barros, George M. Navarro
• de Lima, Marcos
• Scheinberg, Phillip
• Guerino-Cunha, Renato L.

Titel

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Ist Teil von

• Hematology, Transfusion and Cell Therapy, 2021-11, Vol.43 (Suppl 2), p.S3-S12

Ort / Verlag

Elsevier España, S.L.U

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications.